Upgrade to SI Premium - Free Trial

Credit Suisse Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral

August 8, 2016 6:20 AM
Credit Suisse downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Neutral with a price target of $63.00 following news ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst PT Change Downgrades

Next Articles